Background: It is unknown whether the association of alcohol consumption with prostate cancer risk varies between localized and advanced cases, or between sporadic and familial cases. Methods: We assessed recent alcohol drinking in a population-based case-control study of Swedish men, including 1499 cases and 1130 controls. Drinking status and average volume, frequency, and type of alcohol consumed were evaluated. Unconditional logistic regression was performed to estimate the odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for associations between alcohol consumption and prostate cancer risk. Results: Prostate cancer cases were more likely than controls to be current or former, rather than never, drinkers. However, there was no association between recent total alcohol, beer, wine, and liquor consumption and risk of overall prostate cancer, nor advanced, sporadic, or familial prostate cancer. The OR for risk of overall disease among men who drank more than 135 g of total alcohol per week versus non-drinkers was 1.2 (95% CI: 0.9, 1.5), p trend ¼ 0.12. There was a marginal positive association between alcohol intake and risk of localized disease. Conclusions: We detected no association between recent alcohol consumption and risk of advanced, sporadic, or familial prostate cancer, and a borderline positive association with localized disease.
Introduction
The majority of epidemiologic studies suggest that alcohol drinking is not involved in the development of prostate cancer. A meta-analysis of 35 studies published prior to July 1998 determined that overall, there was no association between alcohol drinking and prostate cancer risk [1] . This finding supported a previous review encompassing epidemiologic studies between 1971 and 1996, which similarly found no evidence of an association between low-to-moderate alcohol consumption and risk of prostate cancer [2] . However, a minority of studies have detected an elevated risk in association with greater volume and/or longer duration of alcohol drinking [3] [4] [5] [6] [7] [8] [9] [10] , while one study found an inverse association [11] . Another recent investigation found no significant association between alcohol intake and risk of prostate cancer, but did report that risk was elevated among men who drank a large volume of alcohol at low frequency (one or two days per week), suggesting that drinking patterns rather than amounts may be associated with disease risk [12] .
Sporadic prostate cancer differs in some etiologic aspects, such as age of onset, from familial or hereditary prostate cancer [13, 14] , and epidemiologic studies suggest that certain risk factors, including body mass index [15] , carotenoid levels [16] , and genetic polymorphisms [17] , also differ between cases with and without a family history of prostate cancer. Other studies have also found that some risk associations, particularly with dietary factors such as fatty acids [18] , allium vegetables [19] , and selenium [20] , may vary between localized and advanced cases of prostate cancer. There is no consensus as to whether the association of alcohol drinking with risk of prostate cancer varies between localized and advanced cases, or between cases with and without a family history of prostate cancer. Few, if any, other epidemiologic studies of alcohol consumption have stratified analyses between these subgroups.
Because prostate cancer ranks as the second most common cancer among men in developed countries worldwide [21] , and because alcohol consumption is a common and therefore potentially important, as well as modifiable, risk factor for prostate cancer, their association should be clarified through careful investigation in large studies with detailed information on amount, frequency, and type of alcohol intake. To this end, we have conducted a population-based case-control study of alcohol drinking and risk of prostate cancer in Swedish men.
Methods

Study population
Cancer Prostate in Sweden (CAPS) is a populationbased case-control study of prostate cancer etiology. Incident prostate cancer cases were identified from four of the six regional cancer registries in Sweden, serving the northern, central, Stockholm, and south-eastern health care regions, which encompass approximately 67% of Sweden's total population of about nine million inhabitants. Together, the Swedish cancer registries cover almost 100% of all incident cases in the country [22] . All cases were diagnosed with pathologically or cytologically verified adenocarcinoma of the prostate (ICD-10 code: C61). Residents of the Ö rebro area and northern Sweden were eligible beginning in January 1st, 2001, while men from Va¨stmanland, So¨dermanland, Ga¨vleborg, Dalarna, Va¨rmland, and Uppland were eligible starting 1st July, 2001. Enrollment continued until 30 September, 2002, except in Ja¨mtland and Va¨sterbotten counties, where recruitment ended on 1 March, 2002. Participants from the northern and central health care regions were between 45 and 79 years of age, while those from the south-eastern and Stockholm regions were between 45 and 65 years. In the latter regions, cases under age 65 years were oversampled in order to enrich the proportion of familial cases (those with a family history of prostate cancer), who tend to be diagnosed at an earlier age than sporadic cases.
Controls were identified through the continuously updated Swedish Population Registry database, and frequency-matched by age (five-year categories) to the expected distribution of incident cases.
Among the Swedish residents in the four included health care regions, 1895 eligible cases of prostate cancer were identified during the study period. Of these, 1499 cases (79%) consented to complete a questionnaire for the study. In the same time period and geographic area, 1684 eligible individuals were identified from the general population and asked to participate as controls. Of these, 1130 controls (67%) participated. All study participants granted informed consent at the time of enrollment in the study. This investigation was approved by the Karolinska Institutet and Umea˚University Ethics Committees.
Exposure assessment
Participants completed a self-administered written questionnaire assessing known and potential risk factors for prostate cancer. Respondents were asked whether, one year ago, they drank alcohol at all, or whether they had stopped drinking at some age. If they drank alcohol one year ago, they were asked whether they drank medium beer, strong beer, wine, strong wine, or liquor, on average, never, 0-1 times per month, 2-3 times per month, 1-2 times per week, 3-4 times per week, 5-6 times per week, 1 time per day, 2 times per day, or 3 or more times per day, one year prior to the time of the questionnaire. They were also asked how much, in centiliters, they drank of each type of alcohol on an average occasion. In a separate section, subjects were asked how many times per week, on average, they drank a glass of light beer. However, those who drank only light beer but no other forms of alcohol were considered non-drinkers, since according to Swedish custom light beer is considered a soft drink, and is marketed and sold without any of the restrictions on regular forms of alcohol. Therefore, light beer did not count toward number of alcoholic drinks per week, but was included in total grams of alcohol consumed per day.
Former drinkers were defined as individuals who had stopped drinking at least a year and a half ago, in order to ensure that only men who had not been drinking for at least one full year were included. Persons who stopped drinking within the last year and half were considered current drinkers. For individuals who provided only either frequency or volume, the missing value was assumed to be the median in the study population. Seven men (six cases, one control) were missing data on both frequency and volume of alcohol intake, and were excluded from the analysis.
Frequency and volume of alcohol intake were converted into weekly intake of ethanol in grams. In Sweden, an average can (33 cl) of light beer, medium beer, or strong beer contains 6.0 g (2.3%), 9.1 g (3.5%), or 14.6 g (5.6%) ethanol, respectively; a glass (15 cl) of wine or strong wine contains 14.2 g (12.0%) or 20.7 g (17.5%) ethanol, respectively; and a shot glass (4 cl) of liquor contains 12.6 g (40%) ethanol. To calculate number of drinks per week, one can of medium or strong beer, one glass of wine, and one shot glass of liquor were each considered as one drink.
The validity of alcohol intake estimates in a similar questionnaire was previously evaluated in a group of 248 Swedish men 40-74 years old. Responses to a onetime food frequency questionnaire were compared to fourteen 24-h recall interviews. The Spearman correlation coefficient between the questionnaire-based and interview-based estimates was r ¼ 0.8 for total ethanol intake (M. Messerer et al., submitted).
All participants who reported at least one family member with prostate cancer were contacted again to obtain a more detailed family history. All occurrences of cancer in the family and their dates of diagnosis were verified through either medical record searches or linkage to cancer registries. Cases who had at least one verified close (first-or second-degree) relative with prostate cancer were classified as familial cases; those without a family history of prostate cancer were classified as sporadic cases.
Clinical data, including TNM (tumor, nodes, and metastasis) stage [23] , tumor differentiation grade, Gleason score, serum prostate-specific antigen (PSA) level at diagnosis, means of diagnosis, and primary treatment, were obtained from linkage to the National Prostate Cancer Registry for 95.3% of all patients in the study. Advanced cases were defined as those with at least one of the following criteria: tumor (T) stage ¼ III or IV, nodes (N) stage ¼ I, metastasis (M) stage ¼ I, tumor grade ¼ III, Gleason score ¼ 8-10, or PSA level ‡ 100 ng/ml. These criteria were chosen to identify advanced cases as those with a very high likelihood of dying from the disease. Localized cases were those not meeting any of the above criteria.
Statistical analysis
Crude differences in characteristics between cases and controls were evaluated by v 2 tests (for categorical variables) or two-sided t-tests (for continuous variables). Unconditional logistic regression was performed to estimate the odds ratios (ORs) for prostate cancer, and the corresponding 95% confidence intervals (CIs), associated with average weekly intake of alcohol, adjusting for age (five-year categories) only, or for age and additional variables. Non-drinkers were used as the reference group for all comparisons. Former drinkers were excluded from analyses of alcohol intake, since they did not provide information about past drinking habits.
Other potential confounders, including smoking history (ever, never), body mass index (<25 kg/m 2 , 25-29.9 kg/m 2 , 30-34.9 kg/m 2 , ‡35.0 kg/m 2 ), family history of prostate cancer (yes, no, don't know), diet (quartiles of dairy, red meat, and fruit and vegetable consumption), birth in Sweden (yes, no), and level of education (0-9 years ¼ low, 10-12 years ¼ medium, 13+ years ¼ high), were considered based on prior knowledge of risk factors for prostate cancer, as well as change-in-estimate criteria [24] and likelihood ratio tests comparing models with and without adjustment for additional covariates. Tests for linear trend were performed using the median value in each category of alcohol consumption. All statistical tests were twosided. Analyses were performed using the SAS System software, release 8.2 (SAS Institute Inc., Cary, NC, 1999-2001).
Results
The distribution of demographic characteristics and alcohol consumption in the study population is presented in Table 1 . Cases and controls did not differ significantly with respect to smoking history, body mass index, or level of education; cases were about two times more likely than controls to have a family history of prostate cancer. Table 2 shows the estimated associations between current or former versus never drinking, as well as alcohol intake in terms of grams of ethanol consumed per week, and risk of prostate cancer. These estimates did not differ appreciably from those defining alcohol intake in terms of drinks per week, which are therefore not presented. After adjusting for age, cases were significantly more likely than controls to be current or former drinkers, compared to never-drinkers. The relative risk was somewhat higher in former drinkers than in current drinkers, and persisted after additional adjustment for other factors including smoking history, body mass index, family history of prostate cancer, dietary intake of dairy products, red meat, and fruits and vegetables, birth in Sweden, and/or education.
However, cases and controls were similar in their average recent intake of total alcohol, beer, wine, and liquor (Table 2 ). Compared to non-drinkers, there was no difference in risk of prostate cancer among drinkers of any amount of any type of alcohol, adjusting for age and intake of other alcohol types. Although there was a slight suggestion of a positive association between total alcohol intake and risk of prostate cancer, all ORs were statistically non-significant, and there was no trend in increasing risk with greater consumption of alcohol. When current drinkers were categorized into quartiles based on the distribution among controls, then compared to non-drinkers, the overall findings were the same (data not shown). The estimates were minimally affected (<10% change) by additional adjustment for the other variables listed above. When localized and advanced prostate cancer cases were examined separately, former drinkers were at higher risk of both localized and advanced prostate cancer than never drinkers, and current drinkers had a higher risk of localized disease only (Table 3) . Although not statistically significant, there was marked heterogeneity in the association of total alcohol intake with risk of localized (n ¼ 634 cases) versus advanced (n ¼ 804 cases) prostate cancer, with a positive association between total alcohol consumption and localized disease only. Furthermore, all individual types of alcohol were at least marginally positively associated with risk of localized but not advanced prostate cancer. However, there was no evidence of a dose-response trend in either disease group. These estimates did not change significantly after additional adjustment for the other covariates described earlier (data not shown). The associations with risk of advanced prostate cancer did not differ appreciably from those with risk of overall disease. We also examined heterogeneity of the association with alcohol between invasive (N stage ¼ 0 and M stage ¼ 0; n ¼ 212) and metastatic (N stage ¼ 1 or M stage ¼ 1; n ¼ 191) prostate cancer. We found no appreciable differences in the results compared to the analysis of in versus advanced disease, although sample sizes were small, leading to unstable estimates (data not shown).
Cases with (n ¼ 387) and without (n ¼ 593) a family history of prostate cancer in at least one first-or seconddegree relative were evaluated separately, in order to determine whether the association with alcohol intake Odds ratio adjusted for age (5-year categories), smoking history (ever, never), current body mass index, family history of prostate cancer, and intake of other alcohol types, dairy products, red meat, and fruits and vegetables. differed between sporadic and familial prostate cancer. Whereas current and former drinkers were more likely than never drinkers to develop sporadic prostate cancer, they showed no significant differences in risk of familial prostate cancer (Table 3) . As with overall prostate cancer, there was no association between intake of total alcohol, beer, wine, or liquor with risk of either sporadic or familial disease, and there was no heterogeneity in any association with alcohol intake between the two groups. The estimates were minimally affected by further adjustment for additional variables (data not shown).
To examine whether drinking patterns were associated with risk of prostate cancer, we separated alcohol intake into number of drinking occasions per week and volume of alcohol intake per occasion (Table 4) . After adjusting for age, neither frequency nor volume of beer, wine, or liquor consumption was associated with risk of prostate cancer (data not shown). We also grouped individuals into those that drank beer, wine, or liquor at low frequency and low volume, low frequency and high volume, high frequency and low volume, and high frequency and high volume, based on the median frequency and volume among controls who currently drank (with non-drinkers in the low frequency and low volume category). Again, after adjusting for age, there was no association between the frequency and volume of drinking any type of alcohol and risk of prostate cancer (data not shown).
Discussion
Our study suggests that recent intake of total alcohol, beer, wine, and liquor is not associated with risk of prostate cancer. This lack of association was observed for advanced but not localized disease, and for both sporadic and familial prostate cancer. These latter two findings have not been examined in the majority of previous studies of alcohol and prostate cancer, and the ability to differentiate risk associations with sporadic versus familial prostate cancer using verified data may be unique to this study.
Despite the lack of association with any amount of total alcohol intake, we observed that both current and former drinkers had a significantly higher risk of prostate cancer than never-drinkers. However, because actual alcohol, beer, wine, and liquor consumption showed no relationship with prostate cancer risk, the apparent positive association of ever versus never drinking with risk of prostate cancer may be due to other factors correlated with drinking habits. Alternatively, it is possible that only distant past alcohol intake is associated with risk of prostate cancer, leading to a positive association with ever drinking but not with recent intake.
Several biologic mechanisms have been proposed to account for past observations of a positive association between alcohol drinking and prostate cancer risk. These include metabolic activation of environmental carcinogens or procarcinogens by ethanol; chronic exposure to acetaldehyde, the carcinogenic major metabolite of alcohol; oxidative stress and damage due to increased production of reactive oxygen species [25, 26] ; and immune suppression due to heavy ethanol consumption [27, 28] .
On the other hand, alcohol could conceivably decrease risk of prostate by lowering serum levels of androgens [29, 30] , which appear to promote the development of prostate cancer [31] , and/or raising levels of estrogens [32, 33] . However, epidemiologic studies of alcoholics have demonstrated either no association or even a positive association between long-term alcohol use and prostate cancer risk [34] [35] [36] . Furthermore, moderate alcohol intake appears to be poorly correlated with serum androgen levels [37] .
Differences in associations between localized and advanced prostate cancer could arise if the timing of the effects of alcohol were limited to early disease development, such that any association with late-stage disease would be attenuated over time. Alternatively, alcohol could promote a clinically less aggressive form of prostate cancer. It could also be that disease symptoms altered drinking habits even a year before diagnosis in advanced cases, leading them to report patterns that were unrepresentative of previous intake, whereas habits of men who went on to develop localized prostate cancer were unaffected by symptoms.
Previously observed differences in risk factor associations between sporadic and familial prostate cancer could be explained by interactions between exposures and disease susceptibility genes, relatively lower sensitivity of familial cases to non-genetic risk factors [16] , or age-related differences, as in hormone levels [15] , since familial cases tend to be diagnosed earlier than sporadic ones [13, 14] . However, we did not detect any appreciable heterogeneity in associations with sporadic versus familial prostate cancer.
Our findings contradict a handful of studies that detected a positive association between alcohol intake and risk of all prostate cancer [3] [4] [5] [6] [7] [8] [9] [10] . As with the very modest relative risks that we detected in association with localized disease, the excess risk in these studies has generally been low or moderate, with only a couple of studies [9, 38] reporting relative risks above 2.0 for longterm and/or heavy drinkers, compared to non-drinkers.
Our data also conflict with a report of an inverse association between alcohol drinking and prostate cancer risk in a large prospective cohort study [11] , although the apparent protective effect in this investigation was detected mainly among a small number of men who drank heavily in the distant past. Overall, our findings confirm the majority of studies (summarized in [1, 2] ), which show no association of alcohol consumption with prostate cancer risk.
Inconsistency among prior studies may be explained by several aspects, including variation in study design, study population, exposure assessment, and prevalence of environmental and/or genetic co-factors. Volume, frequency, and duration of drinking have not always been evaluated separately in prior studies. The timing of alcohol exposure being addressed (e.g., current or ten years ago) has varied among study questionnaires, and different types of alcoholic beverages have often not been assessed individually. In addition, the wide geographical and ethnic variation in prostate cancer incidence [39] suggests that environmental and/or genetic exposures play an important role in disease etiology. Hence, results could be affected by both effect modification and uncontrolled confounding by other risk factors. Finally, given that we observed a positive association only with risk of localized prostate cancer, variation in the proportions of localized and advanced cases among previous study populations may explain discrepant results.
Several limitations in our study should be taken into account. We did not obtain information on duration of alcohol drinking, age at onset, cumulative intake, or changes in alcohol drinking patterns over time, some or all of which may affect the association between alcohol intake and prostate cancer risk. We only asked about average alcohol intake one year ago, whereas distant past alcohol intake may be more relevant to prostate cancer risk and/or very different from recent intake. However, distant past exposures are problematic to ascertain because they depend on participants' memory of exposure history.
Although there is no known association between alcohol intake and risk of prostate cancer in the general population, heavy alcohol drinking could be perceived as a generally unhealthy behavior, leading to some overreporting among cases who attributed their disease partly to alcohol intake. This could account for the apparent positive association of current and former drinking with prostate cancer risk, and could have obscured any true inverse association with alcohol consumption. Reasons for non-participation may also have varied between cases and controls. If eligible controls who drank heavily were less likely to participate than light or non-drinkers, this would also have inflated the apparent association between alcohol intake and prostate cancer risk.
Similarly, our observation that never drinkers had a lower risk of prostate cancer than ever drinkers may have been confounded by behavioral factors related to a healthy lifestyle, such as diet and physical activity, that may be associated with disease risk. That is, if nondrinking is a marker of generally healthy behavior, then other lifestyle characteristics could account for the observed inverse association with prostate cancer risk. However, the literature suggests that moderate alcohol consumption, especially of wine, is more positively correlated with a healthy lifestyle than is non-drinking [40] . We did control for all dietary factors found to be associated with prostate cancer risk in our study, but there remains the possibility of residual confounding due to imperfect measurement of dietary habits and other factors.
Former drinkers may have stopped drinking due to heavy alcohol consumption and dependency, poor health, or other factors that increase the risk of prostate cancer, all of which could result in an apparently elevated risk of prostate cancer relative to non-drinkers. Although we were able to adjust for a series of possible risk factors and found almost no change in the estimates of association, there may still be residual or uncontrolled confounding. We were unable to evaluate the association between alcohol intake and risk of prostate cancer among former drinkers, since they were not asked to report their alcohol consumption prior to stopping. The observed positive association with risk of localized prostate cancer may also be explained by chance, especially given that we tested many associations in this study, the apparent association was only marginally significant, and there was no dose-response trend.
In summary, our results are consistent with the preponderance of evidence suggesting that alcohol drinking is unrelated to risk of prostate cancer. Furthermore, we observed that alcohol intake is not associated with risk of advanced, sporadic, or familial prostate cancer, although it is marginally associated with risk of localized disease. Our study was conducted in the relatively homogeneous population of Sweden, where 95% of our study population was born and still resides. Therefore, our results may not be generalizable to other populations, especially those with greater racial and ethnic diversity and/or different alcohol drinking customs. However, because our findings of no association between alcohol and risk of prostate cancer are similar to those from other studies, our results concerning risk of localized, advanced, sporadic, and familial disease may also apply to other populations. Although previous studies have extensively examined the association between alcohol intake and prostate cancer, no others, to our knowledge, have stratified between localized and advanced or sporadic and familial cases. Other studies, especially with prospective exposure data, can help to reveal whether the heterogeneity of the association between localized and advanced prostate cancer is due to bias or a true difference.
